← Back to articles

MSD Animal Health Launches Nobivac NXT RNA Cat Vaccines Across the European Union

Updated 2026-10-28

Article coverImage source

MSD Animal Health — the veterinary arm of Merck & Co., Inc. — began commercial sales of its Nobivac NXT feline vaccine portfolio in the EU in October 2026. The six‑component product line is the first veterinary vaccine in Europe to employ a self‑amplifying RNA (saRNA) particle platform, offering adjuvant‑free formulations, a reduced 0.5 mL dose, a one‑week onset of immunity and up to three years of protection against several core feline pathogens.

A new platform for feline vaccination

The Nobivac NXT vaccines are produced by Intervet International B.V. in Boxmeer, the Netherlands. Each dose combines traditional live‑attenuated strains with a novel saRNA replicon derived from the attenuated TC‑83 strain of Venezuelan equine encephalitis virus. The replicon carries the envelope glycoprotein gene (gp85) of feline leukemia virus (FeLV) strain A/Glasgow‑1. After subcutaneous injection, the particle enters host cells, briefly self‑amplifies its RNA and expresses the FeLV antigen, stimulating both cellular and humoral immunity without generating infectious virus or requiring an adjuvant.

The vaccine composition is as follows:

AntigenFormStrain
Feline herpesvirus‑1 (FHV‑1)Live attenuatedG2620A
Feline calicivirus (FCV)Live attenuatedF9
Feline panleukopenia virus (FPLV)Live attenuatedMW‑1
Chlamydia felisLive attenuatedBaker
Feline leukemia virus (FeLV)saRNA replicongp85 (A/Glasgow‑1)

All components are formulated in a 0.5 mL lyophilised suspension that is adjuvant‑, preservative‑, thimerosal‑ and antibiotic‑free. The lyophilisate is stored at 2 °C–8 °C, protected from light, and must be reconstituted immediately before use; the reconstituted vaccine remains viable for only 30 minutes. Vials are supplied in packs of five or twenty‑five single‑dose glass vials.

Regulatory pathway and European launch

The EU marketing authorisation process began with a positive opinion from the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) on 16–17 April 2026. The CVMP subsequently issued additional favourable opinions for companion‑animal variants in May 2026. The European Commission granted a centralised marketing authorisation (EU/2/26/365/001‑002) between 29 July and 31 July 2026, enabling distribution throughout all EU Member States.

MSD Animal Health introduced the product at the 51st World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland, on 13–15 October 2026. The launch covers the full six‑antigen portfolio, marketed under the Nobivac NXT brand.

Regulatory coverage differs across the United Kingdom. Under the Northern Ireland Protocol, the vaccine is authorised for use in Northern Ireland as part of the EU single market for veterinary medicines. In Great Britain (England, Scotland, Wales) the product has not yet received a separate UK Veterinary Medicines Directorate (VMD) authorisation, so it cannot be marketed there as of October 2026.

Clinical data underpinning efficacy and safety

The EMA’s CVMP evaluated 15 controlled laboratory studies and one multicentre field trial involving 142 client‑owned cats under routine veterinary care. Key findings include:

Safety profile was characterised by mostly mild, transient reactions. The most common events (1–10 % of cats) were localized swelling at the injection site and a brief rise in body temperature (≥ 39.7 °C) lasting less than 24 hours. Very rare events (< 0.01 %) included transient limping in kittens, linked to the live FCV component. Because the vaccine contains live‑attenuated FHV‑1, FCV and FPLV, shedding of these agents can occur for up to 14 days post‑vaccination; while non‑pathogenic to the vaccinated animal, shedding may transmit vaccine strains to unvaccinated contacts. The product is contraindicated in pregnant queens because of the live FPLV component.

Market context and owner attitudes

MSD cited a global survey of more than 5 000 cat owners conducted shortly before the European launch. The survey revealed low perceived necessity for routine feline vaccination: only 16 % of respondents believed vaccination was essential for cat health, while 27 % declined vaccination because they considered their cat “healthy” or “indoor‑only.” Veterinarians remain the primary information source for 58 % of owners, yet only 23 % of surveyed veterinarians reported regularly providing educational materials on feline infectious disease prevention. These gaps highlight the potential impact of a vaccine that simplifies dosing, shortens the immunity window and removes adjuvants—factors often cited by owners as concerns.

Reception within the veterinary community

Professional bodies such as the WSAVA and the Feline European College of Veterinary Anaesthetists (FECAVA) have welcomed the saRNA technology as a meaningful advance. Removing adjuvants addresses longstanding worries about feline injection‑site sarcomas (FISS), a rare tumour linked historically to adjuvanted vaccines. The EMA’s CVMP explicitly concluded that the replicon particles do not integrate into the host genome, do not produce infectious RNA virus particles and have an acceptable tolerability profile.

Conversely, some online commentators and pet‑care influencers have raised safety questions, drawing parallels to human mRNA vaccine debates. Their arguments focus on the short observation periods in early trials (typically 14 days) and speculate about potential chronic immune effects. The EMA’s assessment addressed these concerns, finding no evidence of long‑term adverse outcomes in the data submitted for authorisation.

Remaining uncertainties

The launch of Nobivac NXT marks a pivotal moment for veterinary immunisation, introducing a self‑amplifying RNA platform that could set a precedent for future companion‑animal vaccines.


References:

msd-animal-health.com

vettimes.com

pei.de

lww.com

merck-animal-health-usa.com

msd-tiergesundheit.de

europa.eu

medicinesdatabase.be

europa.eu

nih.gov

nih.gov

europa.eu

europa.eu

noahcompendium.co.uk

msd-tiergesundheit.de

merck.com

vaccinenation.org

investing.com

europa.eu

wsava-congress.org

Explore more articles →Page views: 23